While manipulating the pre-existing anti-Gal response may facilitate an efficacious vaccine response through antigen spreading to antitumor T-cell response, truly tumor-specific antigens are needed to contribute decisively to tumor regression [165]. The gene discussed is GAL; the disease is neoplasm.